CA Patent

CA2867723C — Treatment of brain cancer

Assigned to Array Biopharma Inc · Expires 2022-11-08 · 4y expired

What this patent protects

ABSTRACT An amorphous solid dispersion of compounds for the treatment of brain cancer having ErbB2 over-expression or amplification is provided herein. CA 2867723 2019-04-24

USPTO Abstract

ABSTRACT An amorphous solid dispersion of compounds for the treatment of brain cancer having ErbB2 over-expression or amplification is provided herein. CA 2867723 2019-04-24

Drugs covered by this patent

Patent Metadata

Patent number
CA2867723C
Jurisdiction
CA
Classification
—
Expires
2022-11-08
Drug substance claim
No
Drug product claim
No
Assignee
Array Biopharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.